Cryoport, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; the filing excerpt provides selected fourth-quarter data but does not clearly state fourth-quarter revenue.
Business context
Cryoport provides temperature-controlled logistics, storage, bioservices, processing and cryogenic equipment to life sciences, animal health and reproductive medicine customers. It operated in one reportable segment, serving more than 3,000 customers through a global network of over 50 locations. At year-end, it supported 675 clinical trials, including 82 Phase 3 trials, and 12 commercial therapies.
Financial results and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $233.3 million | $237.3 million |
| Service revenue | $144.1 million | $133.9 million |
| Product revenue | $89.2 million | $103.4 million |
| Gross margin | $99.3 million; 42.6% | $103.9 million; 43.8% |
| Operating loss | $115.2 million | $31.9 million |
| Net loss | $99.6 million | $37.3 million |
| Net loss attributable to common stockholders | $107.6 million | $45.3 million |
| Adjusted EBITDA (non-GAAP) | $(8.3) million | $13.9 million |
| Net cash used in operating activities | $0.8 million | $1.9 million |
- Year-end liquidity: Cash and cash equivalents of $46.3 million, short-term investments of $410.4 million, and working capital of $489.5 million. Management said these resources, together with projected cash flows, were expected to meet operating and capital needs for at least 12 months.
- Debt: Convertible notes had $385.5 million aggregate principal outstanding ($14.3 million due 2025 and $371.2 million due 2026); their net carrying value was $378.6 million. Total liabilities were $468.7 million.
- Cash flows and investment: Investing activities provided $36.0 million, mainly reflecting short-term investment maturities; financing activities used $23.8 million, primarily for a $25.0 million repurchase of 2026 notes. Capital expenditure and software development costs were $38.8 million and $5.2 million, respectively.
- Fourth quarter: The filing reports a fourth-quarter GAAP net loss of $62.4 million and adjusted EBITDA loss of $6.6 million. The excerpt does not provide a clear fourth-quarter revenue figure.
Material changes versus 2022
- Revenue declined 1.7%: service revenue grew 7.6%, but product revenue fell 13.8%, primarily amid lower demand for cryogenic freezer systems, particularly in China.
- BioStorage/BioServices and commercial cell and gene therapy service revenue grew 44.7% and 32.5%, respectively. The company added 21 supported clinical trials year over year.
- Gross margin fell 1.2 percentage points. Service margin was 43.2% versus 43.8%; product margin was 41.6% versus 43.7%, with inflation-related manufacturing costs and safety-stock effects cited among the drivers.
- SG&A rose 22.3% to $146.9 million, and engineering and development expense increased 14.7% to $18.0 million, reflecting expansion, staffing, acquisition/integration activity and platform development.
- Cryoport recorded a $49.6 million goodwill impairment for MVE, driving much of the increased operating and net loss. Goodwill remaining at MVE year-end was $55.2 million; the carrying value approximated estimated fair value.
- In September, Cryoport repurchased $31.3 million principal amount of 2026 notes for $25.0 million cash and recorded a $5.7 million gain on extinguishment.
Outlook, commentary and risks
- Management expects continued investment in supply-chain initiatives, geographic expansion and technology, and anticipated near-term operating losses. It expects clinical trials and commercialization of cell and gene therapies to support future growth, but provided no specific numerical revenue or earnings guidance in the filing excerpt.
- The company said two IntegriCell centers of excellence—in Houston and Liège—were expected to be ready for validation in the first quarter of 2024.
- Key risks include sustained product-demand weakness, delayed clinical trial starts or therapy ramps, inflation and foreign-exchange movements, reliance on certain suppliers and transport partners, acquisition integration, cybersecurity and regulatory compliance, and potential damage to temperature-sensitive products or biological materials.
- One customer represented 10.5% of 2023 revenue. International customers generated 45.5% of revenue.
- The 2022 New Prague facility fire had an estimated $9.4 million revenue impact, primarily in first-quarter 2022. Cryoport reported $15.1 million of cumulative insurance proceeds through year-end 2023 and a $2.6 million insurance-related gain in 2023.
- The company reported no product recalls in 2023 and no known legal proceedings expected to have a material adverse effect. Management and the auditor concluded internal control over financial reporting was effective at year-end.
Important facts for investors to verify
- Whether service growth can persist and offset continued weakness in cryogenic equipment and other product sales, especially in China.
- The assumptions behind the MVE goodwill valuation and the possibility of additional impairment.
- Cash generation, planned investment needs and the refinancing, repayment or conversion path for the $14.3 million 2025 notes and $371.2 million 2026 notes.
- Whether the growth pipeline—675 trials, including 82 Phase 3, and 12 commercial therapies—translates into sustained commercial revenue and improved margins.
- Customer concentration, acquisition earn-outs and integration costs, and potential dilution from convertible notes, Series C preferred stock, options and restricted stock units.
- The company’s latest disclosures and results after December 31, 2023; the outlook and liquidity statements in this filing are management expectations, not assurances.